Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has reaffirmed August 18, 2025, as the target date for the announcement of topline data from its Phase II clinical trial of Allocetra™ for patients with moderate to severe knee osteoarthritis. The trial, which has completed its patient follow-ups, aims to assess key endpoints such as safety and changes in knee pain and function. The data from this randomized, controlled, blinded study are currently under analysis and audit. Results are expected to provide insights into the efficacy and safety of Allocetra™ injections, with evaluations set for three, six, and twelve months post-treatment.